PI3K/AKT/mTOR pathway is often activated in cancer due to genetic alterations of the genes implicated in this pathway.
Recently developed therapies are typically based on targeting the MAP kinase pathway, which is activated in melanoma due to mutations in BRAF or NRAS.
On the other hand, several studies have shown that the c-Myc pathway is activated in RCC due to overexpression and amplification of the c-Myc gene.
We assume that the Wss1 protease is activated in smt3-331 due to both the accumulation of ssDNA and SUMO conjugates induced by ongoing genotoxic stress.
The PI3K/AKT is constitutively activated in PELs due to the effect mediated by PEL released cytokines and following KSHV infection [ 23], in particular as an effect of K1 viral protein expression [ 24].
Despite the absence of LMP1, both the canonical and noncanonical NF-κB pathways are constitutively activated in HL due to genetic lesions, auto-and paracrine signals, and expression of TNF receptor (TNFR) family members [[ 47]].
It would be of particular interest to establish whether the RTK/RAS signalling pathway might be activated in GC due to multiple concomitant mutations of genes related to RTK/RAS signalling or concomitant gene amplifications also present in only small subsets of GC (Deng et al, 2012).
- STAT3 is persistently activated in cancer cells due to aberrant activation of JAK, Src and/or other tyrosine kinases.
Our studies revealed that Mar inhibited PI3K activity and downregulated Akt expression and activity, leading to repression of the PI3K/Akt/mTOR pathway, which is constitutively activated in PC3 cells due to the PTEN-null.
Moreover, UPR is often activated in tumor tissues due to the hypoxia condition under which cancer cells are grown [3], [4] and this mild UPR activation is believed to promote cancer progression as it helps to improve ER fitness and overall cell vitality [5], [6], [7], [8].
